-
CatalYm Presents Expanded Clinical and New Preclinical Data from
CatalYm today announced treatment of the first patients in a series of phase 2a cohorts targeting solid tumors, initiating phase 2 development of CTL-002. The trial will evaluate the safety and efficacy of the company’s lead product candidate, the GDF-15 neutralizing antibody CTL-002 (visugromab), at the confirmed target dose in five cohorts in combination with nivolumab in patients that are relapsed/refractory to anti-PD1/-L1 treatment and in one cohort that is anti-PD-1/-L1 naïve. All six target tumor types were identified by translational research data to exhibit GDF-15-mediated tumoral immunosuppression. CTL-002, which the company will going forward refer to as visugromab, the recently approved International Nonproprietary Name (INN) by the World Health Organization, is…
-
CatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002 at SITC Conference
First four dose escalation levels completed showing excellent tolerability for CTL-002 as monotherapy and in combination with PD-1 Preliminary pharmacodynamic analyses at early dose levels indicate CTL-002-mediated selective T cell shift into the tumor microenvironment Preclinical in vivo study validates relevance of GDF-15 as an exciting novel immuno-oncology target CatalYm today announced the presentation of expanded clinical and new preclinical data for its lead candidate CTL-002, an antibody targeting the novel cancer target GDF-15, at the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting. The results will be presented in two poster presentations on November 13, 2021 and will include data from the ongoing first-in-human trial “GDFather” (GDF-15 Antibody-mediated…
